Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

BACKGROUND: Correlations between development of hand–foot syndrome (HFS) and efficacy in patients receiving capecitabine (CAP)-containing therapy are reported in the literature. We explored the relationship between HFS and efficacy in patients receiving CAP plus bevacizumab (BEV) in the TURANDOT ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Zielinski, Christoph, Lang, Istvan, Beslija, Semir, Kahan, Zsuzsanna, Inbar, Moshe J, Stemmer, Salomon M, Anghel, Rodica, Vrbanec, Damir, Messinger, Diethelm, Brodowicz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815806/
https://www.ncbi.nlm.nih.gov/pubmed/26657657
http://dx.doi.org/10.1038/bjc.2015.419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815806/
https://www.ncbi.nlm.nih.gov/pubmed/26657657
http://dx.doi.org/10.1038/bjc.2015.419

Ejemplares similares